Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in castration-resistant prostate cancer metastatic to the bone (mCRPC).

被引：0
|
作者：
Snedecor, S. J.
Carter, J. A.
Kaura, S.
Botteman, M.
机构：
[1] Pharmerit North Amer, Bethesda, MD USA
[2] Nova Pharmaceut Corp, Oncol Hlth Econ & Outcomes Res, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4581
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dumb) in prevention of skeletal-related events (SREs) in metastatic breast cancer (rotiC)
    Carter, J. A.
    Snedecor, S. J.
    Kaura, S.
    Botteman, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [2] Cost-effectiveness of denosumab (Dmab) versus zoledronic acid (ZA) for prevention of skeletal-related events (SREs) in patients (pts) with castrate-resistant prostate cancer (CRPC) and bone metastases (BM)
    Rader, Michael E.
    Danese, Mark
    Cong, Ze
    Halperin, Marc
    Qian, Yi
    Goessl, Carsten Dietrich
    Chung, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [3] Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events
    Smith, M. R.
    Coleman, R. E.
    Klotz, L.
    Pittman, K.
    Milecki, P.
    Ng, S.
    Chi, K. N.
    Balakumaran, A.
    Wei, R.
    Wang, H.
    Braun, A.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2015, 26 (02) : 368 - 374
  • [4] COST-EFFECTIVENESS OF DENOSUMAB VERSUS ZOLEDRONIC ACID FOR SKELETAL-RELATED EVENT (SRE) REDUCTION IN BONE-METASTATIC PROSTATE CANCER (MPC) IN THE UK
    Botteman, M. F.
    Carter, J. A.
    Fishman, P.
    Chandiwana, D.
    Bains, M.
    Snedecor, S. J.
    VALUE IN HEALTH, 2012, 15 (07) : A420 - A421
  • [5] Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic
    Cristino, Joaquim
    Finek, Jindrich
    Jandova, Petra
    Kolek, Martin
    Pasztor, Balint
    Giannopoulou, Christina
    Qian, Yi
    Brezina, Tomas
    Lothgren, Mickael
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (08) : 799 - 812
  • [6] Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer
    Graff, Julie N.
    Beer, Tomasz M.
    ONCOLOGY-NEW YORK, 2015, 29 (06): : 416 - 423
  • [7] Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: A comparison with skeletal-related events
    Smith, Matthew R.
    Coleman, Robert E.
    Klotz, Laurence
    Pittman, Kenneth B.
    Milecki, Piotr
    Wei, Rachel
    Balakumaran, Arun
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [8] Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: a comparison with skeletal-related events
    Pittman, K.
    Smith, M.
    Coleman, R.
    Klotz, L.
    Milecki, P.
    Wei, R.
    Balakumaran, A.
    Fizazi, K.
    BJU INTERNATIONAL, 2014, 113 : 23 - 23
  • [9] Lifetime cost-effectiveness of denosumab versus zoledronic for prevention of skeletal-related events (SREs) in patients (pts) with castrate-resistant prostate cancer (CRPC) and bone metastases (BM): United States managed care perspective
    Rader, Michael E.
    Danese, Mark
    Cong, Ze
    Halperin, Marc
    Qian, Yi
    Goessl, Carsten Dietrich
    Chung, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer
    Klaassen, Zachary
    Howard, Lauren E.
    de Hoedt, Amanda
    Amling, Christopher L.
    Aronson, William J.
    Cooperberg, Matthew R.
    Kane, Christopher J.
    Terris, Martha K.
    Freedland, Stephen J.
    CANCER, 2017, 123 (09) : 1528 - 1535
12345